Long non-coding RNA CARLo-5 upregulation associates with poor prognosis in patients suffering gastric cancer.
Accumulating evidence has demonstrated that microRNAs (miRNAs) play critical roles in cancer initiation and development. The present study aims to explore the clinical significance of long noncoding RNA CARLo-5 (CARLo-5) in gastric cancer. CARLo-5 expression in normal gastric tissue, gastric cancer were quantified by Quantitative reverse transcription PCR. The relationship between CARLo-5 expression and the clinical features of gastric cancer was assessed. Kaplan-Meier method with log-rank test was applied to compare survival curves. The univariate and multivariate Cox regression models were employed to evaluate the prognostic value of the CARLo-5 expression in overall survival (OS) and relapse-free survival (RFS). We observed that the relative expression of CARLo-5 in gastric cancer tissues was significantly higher than that of their matched adjacent normal tissues (p < 0.001). High CARLo-5 expression was found to be closely correlated with advanced T stage (p = 0.003), positive distant metastasis (p = 0.009), lymph node involvement (p = 0.001), and poor differentiation (p = 0.001). Furthermore, Kaplan-Meier analysis demonstrated that gastric cancer patients with high CARLo-5 expression had poorer OS (p < 0.001) and RFS (p < 0.001). Finally, univariate and multivariate Cox analysis indicated that high CARLo-5 expression were independent predictors for both OS and RFS. Our findings implicated that CARLo-5 could be considered promising biomarkers for prognosis of gastric cancer.